Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Several new drugs for advanced prostate cancer were approved in the past few years, and the pipelines are bristling with compounds that have diverse mechanisms of action. This article examines current and upcoming treatment modalities and provides a market outlook for prostate cancer.
If Duchenne muscular dystrophy drugs that modulate gene splicing can overcome key hurdles, they could boost enthusiasm for related antisense oligonucleotides in other indications.